Maxim raised the firm’s price target on Context Therapeutics to $10 from $4 and keeps a Buy rating on the shares. The company announced a $100M private placement financing with key healthcare investor groups – an event that points to the potential opportunity for CTIM-76, Context’s bispecific antibody which targets CLDN6 and CD3, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
- Context Therapeutics Secures Funding, Advances Clinical Trials
- Context Therapeutics to sell 64.5M shares at $1.55 in private placement
- Context announces FDA clearance of IND application for Phase 1 trial of CTIM-76
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76